PolyBio Commercialization Advisory Network
The Commercialization Advisory Network is a group of leaders across biotechnology, regulatory strategy, and other sectors working to accelerate the translation of promising Long COVID and related chronic illness discoveries into real-world diagnostics and treatments
PolyBio Research Foundation is working to accelerate the translation of scientific discoveries in Long COVID and related chronic diseases into real-world diagnostics and treatments. Even when promising diagnostics or therapeutic approaches are scientifically validated, many stall before they reach patients — lacking the regulatory, operational, and commercial support required to move from academic discovery into widespread clinical use. Our goal is to help bridge that gap so that validated diagnostics can guide patient care and clinical trials, and so that promising therapeutics can advance more efficiently through development and testing.
To help drive this process, PolyBio has built a Commercialization Advisory Network composed of leaders across biotechnology, venture capital, regulatory strategy, and product development. The Network provides PolyBio-supported teams with access to strategic partners, commercialization guidance, operational expertise, regulatory insight, and connections to capital — helping accelerate the development, validation, clinical testing, and real-world adoption of promising diagnostics and therapeutics.
Advisory Network Leadership
Brandon Johnson
StudioDx
Brandon focuses on accelerating the development and commercialization of next-generation diagnostic technologies.
Devon Campbell
Prodct
Devin is the Founder of Prodct, where he works with scientific and technology-driven organizations to build products that translate complex ideas into scalable real-world tools.
Michael Mina, MD, PhD
AnywhereDx
Michael has played a prominent role in advancing the use of rapid and scalable diagnostics, including during the COVID-19 pandemic, with a focus on how testing can be used to guide public health and clinical decision-making.
Hannah Mamuszka
Alva10
Hannah is the Founder and Managing Partner of Alva10, a healthcare investment firm focused on helping diagnostic companies create strategies for insurance coverage.
Johan Skog
Exosome Diagnostics
Johan is Chief Scientific Officer at Exosome Diagnostics, where he has led the development of exosome-based liquid biopsy platforms for clinical use.
Farnaz Bakhshi
ACS BrightEdge
Farnaz is Director of Innovation at ACS BrightEdge, the American Cancer Society’s mission-driven venture capital and innovation arm, where she focuses on advancing high-impact healthcare technologies from early discovery to commercialization.
Todd Sherer, PhD
The Michael J. Fox Foundation for Parkinson’s Research
Todd is the Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research, where he leads one of the largest nonprofit efforts focused on accelerating therapeutic development for Parkinson’s disease.
Gregory W. Mitchell, PhD
Faegre Drinker
Gregory is a partner in the intellectual property practice at Faegre Drinker, where he focuses on patent strategy and technology transactions in the life sciences, biopharmaceutical, and clean technology sectors.
Nelson Rosario
Rosario Tech Law
Nelson is a technology lawyer and founder of Rosario Tech Law, a firm advising companies at the forefront of emerging technologies including AI, blockchain and open-source commercialization opportunities.
Marc Elia
Invivyd
Marc Elia is the Founder and CEO of Invivyd, where he leads the development of antibody-based therapies for infectious diseases. He has experience advancing therapeutics through clinical translation and commercialization.
Tara Kieffer, PhD
Enanta Pharmaceuticals
Tara is Chief Product Strategy Officer at Enanta Pharmaceuticals, where she focuses on advancing innovative therapeutic platforms for complex diseases.
Mey Boukenna
PagsGroup
Mey is an investor at PagsGroup, where she focuses on advancing emerging healthcare and life sciences technologies from early development to commercial deployment.
Omar Khalil
Santé Ventures
Omar is a Managing Director at Santé Ventures, where he focuses on investing in and scaling innovative healthcare and life sciences companies. He has experience in venture capital, company building, and commercialization strategy.
Lee Cooper
Delos Capital
Lee is a Managing Director at Delos Capital, where he focuses on advancing innovative life sciences companies. He has experience in venture investing, company formation, diagnostics, and biopharma strategy.
David Joerg
David Joerg is an entrepreneur, venture investor, and inventor with multiple patents. His career has focused on bringing new technology into commercial use — co-founding the early mobile app Vindigo, leading engineering and research teams at Two Sigma Investments, and now building AI products at Chess.com.
David Isenberg
David is a multi-exit CEO with 30 years experience scaling technology businesses who advises companies on topics such as fundraising, commercial strategy, and building organizations that scale. As someone living with Long Covid, David is deeply committed to accelerating proven treatment solutions.
Jeffrey Ulmer
TechImmune
Jeffrey is President of TechImmune and a vaccine R&D leader with more than 30 years of experience in immunology and biotechnology. He previously held senior research leadership roles at Novartis and GSK Vaccines, focused on advancing innovative vaccine and immunotherapy platforms.
Jochen LennerZ
MGH
Joe is a pathologist and molecular diagnostics expert at Massachusetts General Hospital and Harvard Medical School focused on genomic medicine and digital pathology.